0001193125-20-276104.txt : 20201026 0001193125-20-276104.hdr.sgml : 20201026 20201026081632 ACCESSION NUMBER: 0001193125-20-276104 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20201026 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201026 DATE AS OF CHANGE: 20201026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HCA Healthcare, Inc. CENTRAL INDEX KEY: 0000860730 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062] IRS NUMBER: 273865930 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11239 FILM NUMBER: 201259110 BUSINESS ADDRESS: STREET 1: ONE PARK PLZ CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6153449551 MAIL ADDRESS: STREET 1: ONE PARK PLAZA CITY: NASHVILLE STATE: TN ZIP: 37203 FORMER COMPANY: FORMER CONFORMED NAME: HCA Holdings, Inc. DATE OF NAME CHANGE: 20101126 FORMER COMPANY: FORMER CONFORMED NAME: HCA INC/TN DATE OF NAME CHANGE: 20010627 FORMER COMPANY: FORMER CONFORMED NAME: HCA THE HEALTHCARE CO DATE OF NAME CHANGE: 20010419 8-K 1 d59375d8k.htm FORM 8-K Form 8-K
false 0000860730 0000860730 2020-10-26 2020-10-26

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 26, 2020

 

 

HCA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-11239   27-3865930

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

One Park Plaza, Nashville,

Tennessee

   37203
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (615) 344-9551

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered

Common Stock, $.01 par value per share    HCA    New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company     ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On October 26, 2020, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2020, the text of which is set forth as Exhibit 99.1.

Item 7.01. Regulation FD Disclosure.

On October 26, 2020, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2020, the text of which is set forth as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibits:

 

Exhibit 99.1    Press Release, dated October 26, 2020
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

HCA HEALTHCARE, INC.
 

/s/ William B. Rutherford

 

William B. Rutherford

Executive Vice President and Chief Financial Officer

Date: October 26, 2020

EX-99.1 2 d59375dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO   LOGO

 

 

 

  FOR IMMEDIATE RELEASE
INVESTOR CONTACT:   MEDIA CONTACT:
Mark Kimbrough   Harlow Sumerford
615-344-2688   615-344-1851

HCA Healthcare Reports Third Quarter 2020 Results

Nashville, Tenn., October 26, 2020 – HCA Healthcare, Inc. (NYSE: HCA) today announced its completed financial and operating results for the third quarter ended September 30, 2020.

Key third quarter metrics (all percentage changes compare 3Q 2020 to 3Q 2019 unless otherwise noted):

 

  •  

Revenues totaled $13.311 billion

 

  •  

Net income attributable to HCA Healthcare, Inc. totaled $668 million, or $1.95 per diluted share

 

  •  

Adjusted EBITDA totaled $2.053 billion

 

  •  

Results include reversal of $822 million, or $1.72 per diluted share, in government stimulus income from CARES Act funds

 

  •  

Cash flows from operating activities totaled $2.717 billion

 

  •  

Same facility admissions and same facility equivalent admissions declined 3.8 percent and 9.0 percent, respectively

Consistent with the Company’s preview of third quarter 2020 results, revenues in the third quarter of 2020 increased to $13.311 billion, compared to $12.694 billion in the third quarter of 2019. Net income attributable to HCA Healthcare, Inc. totaled $668 million, or $1.95 per diluted share, compared to $612 million, or $1.76 per diluted share, in the third quarter of 2019. Results for the third quarter of 2020 include a reversal of $822 million, or $1.72 per diluted share, in government stimulus income recorded in the second quarter of 2020 related to general distribution funds received from the Provider Relief Fund established by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act and $14 million, or $0.03 per diluted share, of gains on sales of facilities. Third quarter of 2019 results included losses on retirement of debt of $211 million, or $0.47 per diluted share.

For the third quarter of 2020, Adjusted EBITDA totaled $2.053 billion, compared to $2.285 billion in the third quarter of 2019. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release.

Same facility admissions and equivalent admissions declined 3.8 percent and 9.0 percent, respectively, in the third quarter of 2020, compared to the prior year period. Same facility emergency room visits declined 20.3

 

1

percent in the third quarter of 2020, compared to the prior year period. Same facility inpatient surgeries declined 6.8 percent, and same facility outpatient surgeries declined 6.3 percent in the third quarter of 2020, compared to the same period of 2019. Same facility revenue per equivalent admission increased 14.8 percent in the third quarter of 2020, compared to the third quarter of 2019, due to increases in acuity of patients treated and favorable payer mix in the quarter.

Nine Months Ended September 30, 2020

Revenues for the nine months ended September 30, 2020 totaled $37.240 billion, compared to $37.813 billion in the same period of 2019. Net income attributable to HCA Healthcare, Inc. was $2.328 billion, or $6.79 per diluted share, compared to $2.434 billion, or $6.98 per diluted share, for the first nine months of 2019. Results for the nine months ended September 30, 2020 include losses on sales of facilities of $6 million, or $0.03 per diluted share, and losses on retirement of debt of $295 million, or $0.66 per diluted share. Results for the nine months ended September 30, 2019 included gains on sales of facilities of $17 million, or $0.04 per diluted share, and losses on retirement of debt of $211 million, or $0.47 per diluted share.

Balance Sheet and Cash Flows from Operations

As of September 30, 2020, HCA Healthcare, Inc.’s balance sheet reflected cash and cash equivalents of $6.588 billion, total debt of $30.964 billion, and total assets of $51.016 billion. During the third quarter of 2020, capital expenditures totaled $489 million, excluding acquisitions. Cash flows provided by operating activities in the third quarter totaled $2.717 billion, compared to $2.126 billion in the third quarter of 2019.

CARES Act

During the early days of the pandemic, the Company took a conservative approach which included a number of actions to meet the operational and financial challenges this global health crisis was expected to present. Many aspects of our approach were outlined in our first quarter release.

As noted in our October 8, 2020 release, HCA Healthcare will return, or repay early, all of its share of Provider Relief Fund distributions of approximately $1.6 billion and approximately $4.4 billion in Medicare accelerated payments. The Company is working with the appropriate government agencies to arrange the payment of these funds. The Company expects to fund the entire amount of such payments from available cash and future cash flows from operations.

Earnings Conference Call

HCA Healthcare will host a conference call for investors at 9:00 a.m. Central Daylight Time today. All interested investors are invited to access a live audio broadcast of the call via webcast. The broadcast also will be available on a replay basis beginning this afternoon. The webcast can be accessed at: https://investor.hcahealthcare.com/events-and-presentations.

 

2

About the Company

As of September 30, 2020, HCA Healthcare operated 187 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 21 states and the United Kingdom.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, which involve risks and uncertainties. Forward-looking statements include the Company’s capital allocation, as well as other statements that do not relate solely to historical or current facts. Forward-looking statements can be identified by the use of words like “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “initiative” or “continue.” These forward-looking statements are based on our current plans and expectations and are subject to a number of known and unknown uncertainties and risks, many of which are beyond our control, which could significantly affect current plans and expectations and our future financial position and results of operations. These factors include, but are not limited to, (1) developments related to COVID-19, including, without limitation, related to the length and severity of the pandemic; the volume of canceled or rescheduled procedures and the volume of COVID-19 patients cared for across our health systems; measures we are taking to respond to the COVID-19 pandemic; the impact and terms of government and administrative regulation and stimulus (including the Families First Coronavirus Response Act, the CARES Act, the Paycheck Protection Program and Health Care Enhancement Act and other enacted legislation); changes in revenues due to declining patient volumes, changes in payor mix and deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients); potential increased expenses related to labor, supply chain or other expenditures; workforce disruptions; supply shortages and disruptions; and the timing and availability of effective medical treatments and vaccines, (2) the impact of our substantial indebtedness and the ability to refinance such indebtedness on acceptable terms, as well as risks associated with disruptions in the financial markets and the business of financial institutions as the result of the COVID-19 pandemic which could impact us from a financial perspective, (3) the impact of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the “Affordable Care Act”), including the effects of court challenges to, any repeal of, or changes to, the Affordable Care Act or additional changes to its implementation, the possible enactment of additional federal or state health care reforms and possible changes to other federal, state or local laws or regulations affecting the health care industry, including single-payer proposals (often referred to as “Medicare for All”), and also including any such laws or governmental regulations which are adopted in response to the COVID-19 pandemic, (4) the effects related to the continued implementation of the sequestration spending reductions required under the Budget Control Act of 2011, and related legislation extending these reductions, and the potential for future deficit reduction legislation that may alter these spending reductions, which include cuts to Medicare payments, or create additional spending reductions, (5) increases in the amount and risk of collectability of uninsured accounts and deductibles and copayment amounts for insured accounts, (6) the ability to achieve operating and financial targets, and attain expected levels of patient volumes and control the costs of providing services, (7) possible changes in Medicare, Medicaid and other state programs, including Medicaid supplemental payment programs or Medicaid waiver programs, that may impact reimbursements to

 

3

health care providers and insurers and the size of the uninsured or underinsured population, (8) the highly competitive nature of the health care business, (9) changes in service mix, revenue mix and surgical volumes, including potential declines in the population covered under third-party payer agreements, the ability to enter into and renew third-party payer provider agreements on acceptable terms and the impact of consumer-driven health plans and physician utilization trends and practices, (10) the efforts of health insurers, health care providers, large employer groups and others to contain health care costs, (11) the outcome of our continuing efforts to monitor, maintain and comply with appropriate laws, regulations, policies and procedures, (12) increases in wages and the ability to attract and retain qualified management and personnel, including affiliated physicians, nurses and medical and technical support personnel, (13) the availability and terms of capital to fund the expansion of our business and improvements to our existing facilities, (14) changes in accounting practices, (15) changes in general economic conditions nationally and regionally in our markets, including economic and business conditions (and the impact thereof on the financial markets and banking industry) resulting from the COVID-19 pandemic, (16) the emergence of and effects related to other pandemics, epidemics and infectious diseases, (17) future divestitures which may result in charges and possible impairments of long-lived assets, (18) changes in business strategy or development plans, (19) delays in receiving payments for services provided, (20) the outcome of pending and any future tax audits, disputes and litigation associated with our tax positions, (21) potential adverse impact of known and unknown government investigations, litigation and other claims that may be made against us, (22) the impact of potential cybersecurity incidents or security breaches, (23) our ongoing ability to demonstrate meaningful use of certified electronic health record (“EHR”) technology and the impact of interoperability requirements, (24) the impact of natural disasters, such as hurricanes and floods, or similar events beyond our control, (25) changes in the U.S. federal, state, or foreign tax laws including interpretive guidance that may be issued by taxing authorities or other standard setting bodies, and (26) other risk factors described in our annual report on Form 10-K for the year ended December 31, 2019, our quarterly report on Form 10-Q for the quarter ended June 30, 2020 and our other filings with the Securities and Exchange Commission. Many of the factors that will determine our future results are beyond our ability to control or predict. In light of the significant uncertainties inherent in the forward-looking statements contained herein, readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

All references to “Company” and “HCA Healthcare” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.

 

4

HCA Healthcare, Inc.    

Condensed Consolidated Comprehensive Income Statements    

Third Quarter    

(Dollars in millions, except per share amounts)    

 

     2020     2019  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 13,311       100.0 %    $ 12,694       100.0 % 

Salaries and benefits

      6,097       45.8       5,971       47.0  

Supplies

      2,128       16.0       2,090       16.5  

Other operating expenses

      2,251       16.9       2,352       18.5  

Government stimulus income reversal

      822       6.2       —       —  

Equity in earnings of affiliates

      (40 )      (0.3 )      (4 )      —  

Depreciation and amortization

      694       5.2       647       5.1  

Interest expense

      385       2.9       448       3.5  

Gains on sales of facilities

      (14 )      (0.1 )      —       —  

Losses on retirement of debt

      —       —       211       1.7  
  

 

 

    

 

 

    

 

 

    

 

 

  
     12,323       92.6       11,715       92.3  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      988       7.4       979       7.7  

Provision for income taxes

      209       1.5       215       1.7  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      779       5.9       764       6.0  

Net income attributable to noncontrolling interests

      111       0.9       152       1.2  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

   $ 668       5.0     $ 612       4.8  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 1.95       $ 1.76    

Shares used in computing diluted earnings per share (millions)

      343.346         347.487    

Comprehensive income attributable to HCA Healthcare, Inc.

   $ 715       $ 582    
  

 

 

      

 

 

    

 

5

HCA Healthcare, Inc.    

Condensed Consolidated Comprehensive Income Statements    

For the Nine Months Ended September 30, 2020 and 2019    

(Dollars in millions, except per share amounts)    

 

     2020     2019  
     Amount     Ratio     Amount     Ratio  

Revenues

    $ 37,240       100.0 %    $ 37,813       100.0 % 

Salaries and benefits

      17,545       47.1       17,455       46.2  

Supplies

      5,999       16.1       6,249       16.5  

Other operating expenses

      6,825       18.3       7,013       18.6  

Equity in earnings of affiliates

      (48 )      (0.1 )      (23 )      (0.1 ) 

Depreciation and amortization

      2,059       5.6       1,902       4.9  

Interest expense

      1,201       3.2       1,386       3.7  

Losses (gains) on sales of facilities

      6       —       (17 )      —  

Losses on retirement of debt

      295       0.8       211       0.6  
  

 

 

    

 

 

    

 

 

    

 

 

  
     33,882       91.0       34,176       90.4  
  

 

 

    

 

 

    

 

 

    

 

 

  

Income before income taxes

      3,358       9.0       3,637       9.6  

Provision for income taxes

      665       1.8       765       2.0  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income

      2,693       7.2       2,872       7.6  

Net income attributable to noncontrolling interests

      365       0.9       438       1.2  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc.

   $ 2,328       6.3     $ 2,434       6.4  
  

 

 

    

 

 

    

 

 

    

 

 

  

Diluted earnings per share

    $ 6.79       $ 6.98    

Shares used in computing diluted earnings per share (millions)

      343.014         348.712    

Comprehensive income attributable to HCA Healthcare, Inc.

   $ 2,273       $ 2,354    
  

 

 

      

 

 

    

 

6

HCA Healthcare, Inc.    

Condensed Consolidated Balance Sheets    

(Dollars in millions)    

 

     September 30,     June 30,     December 31,  
     2020     2020     2019  

ASSETS

       

Current assets:

       

Cash and cash equivalents

    $ 6,588     $ 4,638     $ 621  

Accounts receivable

      6,433       6,139       7,380  

Inventories

      1,950       1,834       1,849  

Other

      1,295       1,420       1,346  
  

 

 

    

 

 

    

 

 

  

Total current assets

      16,266       14,031       11,196  

Property and equipment, at cost

      48,775       48,484       47,235  

Accumulated depreciation

      (25,834 )      (25,413 )      (24,520 ) 
  

 

 

    

 

 

    

 

 

  
     22,941       23,071       22,715  

Investments of insurance subsidiaries

      390       364       315  

Investments in and advances to affiliates

      335       275       249  

Goodwill and other intangible assets

      8,570       8,578       8,269  

Right-of-use operating lease assets

      1,972       1,863       1,834  

Other

      542       527       480  
  

 

 

    

 

 

    

 

 

  
   $ 51,016     $ 48,709     $ 45,058  
  

 

 

    

 

 

    

 

 

  

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

       

Current liabilities:

       

Accounts payable

    $ 3,270     $ 2,882     $ 2,905  

Accrued salaries

      1,971       1,631       1,775  

Other accrued expenses

      2,843       3,181       2,932  

Government stimulus refund liability

      6,123       4,999       —  

Long-term debt due within one year

      172       163       145  
  

 

 

    

 

 

    

 

 

  

Total current liabilities

      14,379       12,856       7,757  

Long-term debt, less debt issuance costs and discounts of $245, $252 and $239

      30,792       30,779       33,577  

Professional liability risks

      1,434       1,485       1,370  

Right-of-use operating lease obligations

      1,635       1,531       1,499  

Income taxes and other liabilities

      1,477       1,490       1,420  

EQUITY (DEFICIT)

       

Stockholders’ deficit attributable to HCA Healthcare, Inc.

      (974 )      (1,786 )      (2,808 ) 

Noncontrolling interests

      2,273       2,354       2,243  
  

 

 

    

 

 

    

 

 

  

Total equity (deficit)

      1,299       568       (565 ) 
  

 

 

    

 

 

    

 

 

  
   $ 51,016     $ 48,709     $ 45,058  
  

 

 

    

 

 

    

 

 

  

 

7

HCA Healthcare, Inc.    

Consolidated Statements of Cash Flows    

For the Nine Months Ended September 30, 2020 and 2019    

(Dollars in millions)    

 

     2020     2019  

Cash flows from operating activities:

     

Net income

    $ 2,693     $ 2,872  

Adjustments to reconcile net income to net cash provided by operating activities:

     

Increase (decrease) in cash from operating assets and liabilities:

     

Accounts receivable

      930       (93 ) 

Inventories and other assets

      (36 )      (95 ) 

Accounts payable and accrued expenses

      542       (118 ) 

Government stimulus refund liability

      6,123       —  

Depreciation and amortization

      2,059       1,902  

Income taxes

      (114 )      51  

Losses (gains) on sales of facilities

      6       (17 ) 

Losses on retirement of debt

      295       211  

Amortization of debt issuance costs and discounts

      22       23  

Share-based compensation

      229       263  

Other

      66       98  
  

 

 

    

 

 

  

Net cash provided by operating activities

      12,815       5,097  
  

 

 

    

 

 

  

Cash flows from investing activities:

     

Purchase of property and equipment

      (2,087 )      (2,884 ) 

Acquisition of hospitals and health care entities

      (380 )      (1,592 ) 

Disposition of hospitals and health care entities

      68       49  

Change in investments

      (40 )      35  

Other

      (44 )      17  
  

 

 

    

 

 

  

Net cash used in investing activities

      (2,483 )      (4,375 ) 
  

 

 

    

 

 

  

Cash flows from financing activities:

     

Issuance of long-term debt

      2,700       6,451  

Net change in revolving credit facilities

      (2,480 )      (30 ) 

Repayment of long-term debt

      (3,403 )      (5,289 ) 

Distributions to noncontrolling interests

      (393 )      (404 ) 

Payment of debt issuance costs

      (35 )      (71 ) 

Payment of cash dividends

      (153 )      (414 ) 

Repurchase of common stock

      (441 )      (759 ) 

Other

      (156 )      (145 ) 
  

 

 

    

 

 

  

Net cash used in financing activities

      (4,361 )      (661 ) 
  

 

 

    

 

 

  

Effect of exchange rate changes on cash and cash equivalents

      (4 )      (4 ) 
  

 

 

    

 

 

  

Change in cash and cash equivalents

      5,967       57  

Cash and cash equivalents at beginning of period

      621       502  
  

 

 

    

 

 

  

Cash and cash equivalents at end of period

    $ 6,588     $ 559  
  

 

 

    

 

 

  

Interest payments

    $ 1,230     $ 1,492  

Income tax payments, net

    $ 779     $ 714  

 

8

HCA Healthcare, Inc.    

Operating Statistics    

 

                 For the Nine Months  
     Third Quarter     Ended September 30,  
     2020     2019     2020     2019  

Operations:

         

Number of Hospitals

      187       184       187       184  

Number of Freestanding Outpatient Surgery Centers

      121       125       121       125  

Licensed Beds at End of Period

      49,473       48,588       49,473       48,588  

Weighted Average Licensed Beds

      49,479       48,535       49,333       48,335  

Reported:

         

Admissions

      506,756       527,284       1,487,992       1,568,733  

% Change

      -3.9 %        -5.1 %   

Equivalent Admissions

      835,576       918,964       2,477,747       2,712,339  

% Change

      -9.1 %        -9.8 %   

Revenue per Equivalent Admission

    $ 15,930     $ 13,814     $ 15,214     $ 13,941  

% Change

      15.3 %        9.1 %   

Inpatient Revenue per Admission

    $ 16,265     $ 14,192     $ 15,531     $ 14,297  

% Change

      14.6 %        8.6 %   

Patient Days

      2,593,139       2,530,221       7,476,794       7,667,666  

% Change

      2.5 %        -2.5 %   

Equivalent Patient Days

      4,275,481       4,410,715       12,299,326       13,257,395  

% Change

      -3.1 %        -7.2 %   

Inpatient Surgery Cases

      133,492       143,215       387,228       421,051  

% Change

      -6.8 %        -8.0 %   

Outpatient Surgery Cases

      232,493       249,177       629,723       743,464  

% Change

      -6.7 %        -15.3 %   

Emergency Room Visits

      1,813,661       2,269,364       5,594,484       6,810,141  

% Change

      -20.1 %        -17.9 %   

Outpatient Revenues as a Percentage of Patient Revenues

      35.5 %      39.0 %      35.0 %      38.7 % 

Average Length of Stay (days)

      5.117       4.799       5.025       4.888  

Occupancy

      57.0 %      56.7 %      55.3 %      58.1 % 

Same Facility:

         

Admissions

      493,466       513,170       1,448,444       1,529,423  

% Change

      -3.8 %        -5.3 %   

Equivalent Admissions

      809,284       889,324       2,371,103       2,630,608  

% Change

      -9.0 %        -9.9 %   

Revenue per Equivalent Admission

    $ 15,721     $ 13,691     $ 15,024     $ 13,836  

% Change

      14.8 %        8.6 %   

Inpatient Revenue per Admission

    $ 16,239     $ 14,209     $ 15,525     $ 14,325  

% Change

      14.3 %        8.4 %   

Inpatient Surgery Cases

      129,831       139,345       376,189       409,556  

% Change

      -6.8 %        -8.1 %   

Outpatient Surgery Cases

      224,496       239,530       607,904       716,274  

% Change

      -6.3 %        -15.1 %   

Emergency Room Visits

      1,767,372       2,217,713       5,467,829       6,668,965  

% Change

      -20.3 %        -18.0 %   

 

9

HCA Healthcare, Inc.    

Supplemental Non-GAAP Disclosures    

Operating Results Summary    

(Dollars in millions, except per share amounts)    

 

                 For the Nine Months  
     Third Quarter     Ended September 30,  
     2020     2019     2020     2019  

Revenues

    $ 13,311     $ 12,694     $ 37,240     $ 37,813  

Net income attributable to HCA Healthcare, Inc.

   $ 668     $ 612     $ 2,328     $ 2,434  

Losses (gains) on sales of facilities (net of tax)

      (10 )      —       9       (13 ) 

Losses on retirement of debt (net of tax)

      —       162       227       162  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a)

      658       774       2,564       2,583  

Depreciation and amortization

      694       647       2,059       1,902  

Interest expense

      385       448       1,201       1,386  

Provision for income taxes

      205       264       730       810  

Net income attributable to noncontrolling interests

      111       152       365       438  
  

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA (a)

    $ 2,053     $ 2,285     $ 6,919     $ 7,119  
  

 

 

    

 

 

    

 

 

    

 

 

  

Adjusted EBITDA margin (a)

      15.4 %      18.0 %      18.6 %      18.8 % 

Diluted earnings per share:

         

Net income attributable to HCA Healthcare, Inc.

   $ 1.95     $ 1.76     $ 6.79     $ 6.98  

Losses (gains) on sales of facilities

      (0.03 )      —       0.03       (0.04 ) 

Losses on retirement of debt

      —       0.47       0.66       0.47  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt (a)

    $ 1.92     $ 2.23     $ 7.48     $ 7.41  
  

 

 

    

 

 

    

 

 

    

 

 

  

Shares used in computing diluted earnings per share (millions)

      343.346       347.487       343.014       348.712  

 

(a)

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA should not be considered as measures of financial performance under generally accepted accounting principles (“GAAP”). We believe net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are important measures that supplement discussions and analysis of our results of operations. We believe it is useful to investors to provide disclosures of our results of operations on the same basis used by management. Management relies upon net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA as the primary measures to review and assess operating performance of its health care facilities and their management teams.

Management and investors review both the overall performance (including net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and GAAP net income attributable to HCA Healthcare, Inc.) and operating performance (Adjusted EBITDA) of our health care facilities. Adjusted EBITDA and the Adjusted EBITDA margin (Adjusted EBITDA divided by revenues) are utilized by management and investors to compare our current operating results with the corresponding periods during the previous year and to compare our operating results with other companies in the health care industry. It is reasonable to expect that losses (gains) on sales of facilities and losses on retirement of debt will occur in future periods, but the amounts recognized can vary significantly from period to period, do not directly relate to the ongoing operations of our health care facilities and complicate period comparisons of our results of operations and operations comparisons with other health care companies.    

Net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measures of financial performance under GAAP, and should not be considered as alternatives to net income attributable to HCA Healthcare, Inc. as a measure of operating performance or cash flows from operating, investing and financing activities as a measure of liquidity. Because net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA are not measurements determined in accordance with GAAP and are susceptible to varying calculations, net income attributable to HCA Healthcare, Inc., excluding losses (gains) on sales of facilities and losses on retirement of debt, and Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures presented by other companies.    

 

10

EX-101.SCH 3 hca-20201026.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 hca-20201026_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 hca-20201026_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g59375g1.jpg GRAPHIC begin 644 g59375g1.jpg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g59375g2.jpg GRAPHIC begin 644 g59375g2.jpg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end XML 8 d59375d8k_htm.xml IDEA: XBRL DOCUMENT 0000860730 2020-10-26 2020-10-26 false 0000860730 8-K 2020-10-26 HCA HEALTHCARE, INC. DE 001-11239 27-3865930 One Park Plaza Nashville TN 37203 (615) 344-9551 false false false false Common Stock, $.01 par value per share HCA NYSE false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Oct. 26, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000860730
Document Type 8-K
Document Period End Date Oct. 26, 2020
Entity Registrant Name HCA HEALTHCARE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-11239
Entity Tax Identification Number 27-3865930
Entity Address, Address Line One One Park Plaza
Entity Address, City or Town Nashville
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37203
City Area Code (615)
Local Phone Number 344-9551
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $.01 par value per share
Trading Symbol HCA
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d59375d8k.htm d59375dex991.htm hca-20201026.xsd hca-20201026_lab.xml hca-20201026_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d59375d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d59375d8k.htm" ] }, "labelLink": { "local": [ "hca-20201026_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hca-20201026_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hca-20201026.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hca", "nsuri": "http://www.hcahealthcare.com/20201026", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d59375d8k.htm", "contextRef": "duration_2020-10-26_to_2020-10-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d59375d8k.htm", "contextRef": "duration_2020-10-26_to_2020-10-26", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hcahealthcare.com//20201026/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-20-276104-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-276104-xbrl.zip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end